Metastatic Breast Cancer

Phase II trial of Navelbine plus Herceptin for HER2 looks promising

Published in Women's Health Weekly, December 5th, 2002

New research suggests that the combination of Navelbine (vinorelbine tartrate) Injection, a first-line chemotherapy treatment for advanced non-small cell lung cancer, and the monoclonal antibody therapy Heceptin (trastuzumab) is a promising and generally well tolerated treatment for HER2 positive metastatic breast cancer and warrants further study

Navelbine is not currently indicated for use in women with metastatic breast cancer.

The multicenter open-label trial enrolled 40 women with metastatic disease (spread to sites in the body beyond the breast) whose tumors over-expressed the HER2Neu oncogene, a growth-promoting protein that has been closely...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-12-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry